Lescarden Inc. (OTCBB:LCAR) announced today that it had received full regulatory approval for its new packaging partner, Amcor Contract Packaging of Bethlehem, PA. With this approval Lescarden can resume delivering its proprietary product, Catrix® Wound Dressing, to its distributors in key global markets.

The approval comes after extensive testing and auditing of the Amcor facilities, which have already begun to package the Catrix Wound Dressing.  All regulatory approvals necessary for the delivery of Lescarden's products to its European distributors are now in place.   

William Luther, Lescarden's President, said, "We are pleased to complete this arduous and time-consuming approval process.  Amcor has worked extremely hard to meet the standards required.  We expect that our new relationship with Amcor should enable Lescarden to meet future demand more efficiently and more profitably.  The immediate effect is that Lescarden will now be able to begin to satisfy a substantial order backlog for its Catrix Wound Dressing."

Catrix® Wound Dressing is a specially processed bovine cartilage product in the form of a fine, white powder. The Wound Dressing is approved by the FDA for the management of chronic skin wounds including decubitus ulcers, venous stasis ulcers and diabetic ulcers as well as second degree burns and post-radiation dermatitis. Clinical studies conducted with Catrix® on patients suffering from bed sores have demonstrated its ability to assist patients who had previously been unresponsive to standard wound care treatments. The same studies demonstrated the potential for significant cost savings for both patient and caregiver in the treatment of such non-healing lesions.

Amcor Contract Packaging, formerly known as Alcan Contract Packaging, is a division of Amcor Limited, an Australian-based global packaging manufacturer offering a broad range of plastic, fiber, metal and glass packaging products, along with packaging-related services.

Lescarden, Inc. is a biotechnology company dedicated to the development of natural, biologic therapies for the chronic wound care, dermatology and osteoarthritis markets. For more information please contact the Company at 212- 687-1050 or visit www.catrix.com.

CONTACT:  Lescarden Inc.

212-687-1050
www.catrix.com

Lescarden (CE) (USOTC:LCAR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Lescarden (CE).
Lescarden (CE) (USOTC:LCAR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Lescarden (CE).